DOCSLIB.ORG

DNA Copy Number Amplification Profiling of Human Neoplasms

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
DNA Copy Number Amplification Profiling of Human Neoplasms Oncogene (2006) 25, 7324–7332 & 2006 Nature Publishing Group All rights reserved 0950-9232/06 $30.00 www.nature.com/onc ONCOGENOMICS DNA copy number amplification profiling of human neoplasms S Myllykangas1, J Himberg2,TBo¨ hling1, B Nagy1,3, J Hollme´ n2 and S Knuutila1 1Department of Pathology, Haartman Institute and HUSLAB, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; 2Laboratory of Computer and Information Science, Helsinki University of Technology, Espoo, Finland and 31st Department of Obstetrics and Gynecology, Scmmclwcis University, Budapest, Hungary DNA copy number amplifications activate oncogenes and been shown to increase significantly in breast and are hallmarks of nearly all advanced tumors. Amplified prostate cell lines and in primary tumors, but the genes represent attractive targets for therapy, diagnostics number of overexpressed genes in the amplified chro- and prognostics. To investigate DNA amplifications in mosomal areas varies upon cancer tissue type (Pollack different neoplasms, we performed a bibliomics survey et al., 1999, 2002; Hyman et al., 2002). Amplification- using 838 published chromosomal comparative genomic activated human oncogenes include AKT2 in ovarian hybridization studies and collected amplification data at cancer, ERBB2 in breast and ovarian tumors, MYCL1 chromosome band resolution from more than 4500 cases. in small-cell lung cancer, MYCN in neuroblastoma, Amplification profiles were determined for 73 distinct REL in Hodgkin’s lymphoma, EGFR in glioma and neoplasms. Neoplasms were clustered according to the non-small-cell lung cancer and MYC in various cancers amplification profiles, and frequently amplified chromo- (Futreal et al., 2004). Amplifications are frequently somal loci (amplification hot spots) were identified using observed in advanced cancers, which have lost the p53- computational modeling. To investigate the site specificity mediated maintenance of genomic integrity (Livingstone and mechanisms of gene amplifications, colocalization of et al., 1992; Yin et al., 1992). Amplifications of various amplification hot spots, cancer genes, fragile sites, virus drug target genes have been observed to confer drug integration sites and gene size cohorts were tested in a resistance in several in vitro experiments as well as in statistical framework. Amplification-based clustering clinical studies (Wahl et al., 1979; Johnston et al., 1983; demonstrated that cancers with similar etiology, cell-of- Goker et al., 1995; Shannon, 2002). origin or topographical location have a tendency to obtain DNA copy number amplifications arise as multi- convergent amplification profiles. The identified amplifi- plication of intra-chromosomal regions of 0.5–10 Mb in cation hot spots were colocalized with the known fragile length. In contrast to the definition of amplification, sites, cancer genes and virus integration sites, but DNA copy number increase in larger chromosomal global statistical significance could not be ascertained. areas or intact chromosomes, owing to translocations or Large genes were significantly overrepresented on the aneuploidy, is defined as a gain (Lengauer et al., 1998). fragile sites and the reported amplification hot spots. Amplifications produce excess gene copies in homo- These findings indicate that amplifications are selected in geneously staining regions (HSRs) and extrachromo- the cancer tissue environment according to the qualitative somal acentric DNA fragments (double minutes and traits and localization of cancer genes. episomes) (Albertson et al., 2003). HSRs manifest as a Oncogene(2006) 25, 7324–7332. doi:10.1038/sj.onc.1209717; ladder-like structure of inverted repeats within chromo- published online 5 June 2006 somes (Schwab, 1998). Extrachromosomal amplicons appear as double minutes, which can be seen using Keywords: cancer; gene amplification; fragile site; bio- conventional cytogenetics (Hahn, 1993), and episomes informatics; data mining; molecular pathology (B250 bp in length), which are only detectable using molecular biology methods (Maurer et al., 1987; Graux ONCOGENOMICS et al., 2004). HSRs, double minutes and episomes may contain fused genetic material from different chromo- Introduction somal loci (Guan et al., 1994; Graux et al., 2004). Models for pathways that result in gene amplification Gene amplifications cause an increase in the gene copy have been reviewed in detail by Myllykangas and number and subsequently elevate the expression of the Knuutila (2006). Amplification pathway models predict amplified genes. The expression of amplified genes has that two independent DNA double-stranded breaks at the margins of an amplified region are required to occur Correspondence: S Myllykangas, Department of Pathology, Haartman to enable the amplification of the intra-chromosomal Institute, University of Helsinki, PO Box 21, FI-00014 Helsinki, DNA segment. The human genome is perturbed by Finland. specific labile domains, such as fragile sites, virus E-mail: samuel.myllykangas@helsinki.fi Received 1 February 2006; revised 13 April 2006; accepted 20 April 2006; integration sites and large genes, which are more published online 5 June 2006 sensitive to DNA damage than other loci. Fragile sites Amplification profiling of human neoplasms S Myllykangas et al 7325 are chromosomal regions, in which chromosomal breaks Therefore, amplification hot spots, the genomic loci can be induced using replication-stalling chemicals. that are prone to amplify in human neoplasms, were Based on their prevalence in the population, the fragile identified using computational modeling, specifically the sites (119) are classified as common or rare. Eighty-eight independent component analysis (ICA). Chromosome common fragile sites are found in all individuals and 31 bands with values >0.5 were included in the genome- rare fragile sites in less than 5% of the population. wide ICA factors representing the amplification hot Susceptibility to damage varies between the fragile sites, spots. Values between 0.5 and 1 within the amplification as 75% of the DNA damage lesions have been located to hot spots are shown using gray to black scaling. 22 common fragile sites (out of the 139 chromosomal Figure 1b presents the top 30 identified amplification loci with identified lesions) (Glover et al., 1984). hot spots (10% of all identified independent factors) in Especially, common fragile sites are colocalized with the order of decreasing stability index, which was amplifications (Hellman et al., 2002). WWOX (1.1 Mb) evaluated by bootstrapping the ICA factors. Besides and FHIT (0.8 Mb) are particularly large genes and factor 19, which embodies the whole chromosome 21, located in two of the most damage-prone fragile sites the longest coherent amplification hot spots encom- (16q23.1 and 3p14.2, respectively). WWOX and FHIT passed single chromosome arms. Note that three factors are frequently involved in DNA breaks. Besides fragile are composed of two disjoint regions (factors 9, 12 and site expression, retroviral DNA insertion at specific 27). The disjoint hot spots spanned across the centro- genomic sites is believed to induce DNA breaks. meres of chromosomes 8, 17 and 5, respectively. Amplification hot spots did not cross chromosome boundaries, although this would have been conceivable in the continuous vector presentation of amplifications. Results The amplification hot spots are also presented in Table 1, which lists the fragile sites and cancer genes that DNA copy number amplification profiles of human colocalize with the amplification hot spots. The ampli- neoplasms fication hot spots covered 178 chromosome bands DNA copy number amplifications in human neoplasms (45% of the genome). were extracted from a publicly available data collection. A data matrix containing binary chromosome sub- band-specific information of DNA amplifications was Amplification profile-based clustering reveals relations generated (downloadable at http://www.helsinki.fi/cmg/ between human neoplasms cgh_data.html). The number of examined loci was 393 DNA amplification profiling (Figure 1a) showed that (list of all analysed chromosomal loci in Appendix 1 in amplifications were not randomly distributed in the the Supplementary information). The assembled data human genome, but specific amplifications were ob- matrix contained 4590 cases with 5740 coherent, served in distinct neoplasms. Hierarchical clustering was amplified chromosomal regions. In all, 1 803 870 chro- performed to investigate whether there were amplifica- mosome bands were analysed and 26 527 of them were tion-based similarities between neoplasms. Figure 2 labeled amplified. Appendix 2 in the Supplementary shows the correlation matrix and the dendrogram of information presents an overview of the studied the neoplasms. Four main neoplasm clusters are marked neoplasms (n ¼ 73) and DNA amplifications. The in correlation matrix. majority of the neoplasms were malignant tumors or hematologic malignancies, but non-malignant or pre- Associations between amplification hot spots, cancer malignant lesions were also included in this study. All 73 genes, fragile sites, virus integration sites and gene size neoplasm categories included cases with amplifications. cohorts Amplification profiling was carried out by calculating The identification of amplification hot spots (Figure 1b) chromosome sub-band-specific amplification frequen- suggested that some structural genomic properties or cies. Amplification profiles of all studied neoplasms are labile genomic features might explain the site specificity presented in Figure 1a,
Load more

Recommended publications
  • SS18 (SYT) (18Q11) Gene Rearrangement by FISH Indications for Ordering Genetics
    SS18 (SYT) (18q11) Gene Rearrangement by FISH Indications for Ordering Genetics Diagnosis of synovial sarcoma in conjunction with histologic Translocations – SS18-SSX1, SS18-SSX2 and clinical information Structure/function Test Description • SS18 is located on chromosome 18 • SSX1 and SSX2 are located on the X-chromosome Fluorescence in situ hybridization • Each gene in the translocation codes for proteins that have opposite transcriptional functions Tests to Consider o SS18 – activator of oncogenes Primary test o SSX1, SSX2 – tumor suppression SS18 (SYT) (18q11) Gene Rearrangement by FISH 3001303 Test Interpretation • Molecular diagnosis of synovial sarcoma Results Related test • Positive – SS18 rearrangement is detected Chromosome FISH, Interphase 2002298 o SSX translocation partner is not identified with this • Specific probe for SS18 (SYT) rearrangement must be testing methodology requested o Synovial sarcoma likely • Fresh tissue specimens only • Negative – no SS18 rearrangement detected Disease Overview o Does not entirely exclude the presence of an SS18 rearrangement as some translocations are cryptic and Incidence – rare not evaluable by this testing methodology • Synovial sarcomas account for 8-10% of all soft tissue o Does not entirely exclude diagnosis of synovial sarcoma sarcomas Limitations Diagnostic/prognostic issues • Testing using tissue fixed in alcohol-based or non-formalin • Synovial sarcomas may resemble other neoplasms, fixatives has not been validated using this method particularly those displaying an epithelioid, spindle cell, or • SS18 fusion partners are not detected with this test combined morphology • t(X;18)(p11.2;q11.2) translocation serves as a specific marker for synovial sarcoma o SS18 (SYT) gene fuses with SSX gene . Fusion with SSX1 in ~65% of synovial sarcomas .
    [Show full text]
  • Lupus-Associated Endogenous Retroviral LTR Polymorphism and Epigenetic Imprinting Promote HRES-1/Rab4 Expression and Mtor Activation
    Lupus-associated endogenous retroviral LTR polymorphism and epigenetic imprinting promote HRES-1/Rab4 expression and mTOR activation Aparna Godavarthy, … , Katalin Banki, Andras Perl JCI Insight. 2019. https://doi.org/10.1172/jci.insight.134010. Research In-Press Preview Immunology Graphical abstract Find the latest version: https://jci.me/134010/pdf LUPUS-ASSOCIATED ENDOGENOUS RETROVIRAL LTR POLYMORPHISM AND EPIGENETIC IMPRINTING PROMOTE HRES-1/RAB4 EXPRESSION AND MTOR ACTIVATION Aparna Godavarthy*1, Ryan Kelly*1, John Jimah1, Miguel Beckford1, Tiffany Caza1,2, David Fernandez1,2, Nick Huang1,3, Manuel Duarte1,2, Joshua Lewis1,2, Hind J. Fadel4, Eric M. Poeschla4, Katalin Banki5, and Andras Perl1,2,3 * These authors contributed equally to the study. 1, Division of Rheumatology, Department of Medicine; 2, Department of Microbiology and Immunology; 3, Department of Biochemistry and Molecular Biology, and 5, Department of Pathology, State University of New York, Upstate Medical University, College of Medicine, 750 East Adams Street, Syracuse, New York 13210; 4, Department of Molecular Medicine; Mayo Clinic College of Medicine, 200 First Street SW, Rochester 55905, USA; Correspondence: Andras Perl, M.D., Ph.D. , State University of New York, College of Medicine, 750 East Adams Street, Syracuse, New York 13210; Phone: (315) 464-4194; Fax: (315) 464- 4176; E-mail: [email protected] Key Words: Systemic Lupus Erythematosus, T Cells, HRES-1/Rab4. mTOR, Autoimmunity The authors have declared that no conflict of interest exists. Supplementary Materials include Supplemental Methods and Supplementary Figures S1-S26. 1 ABSTRACT Overexpression and long terminal repeat (LTR) polymorphism of the HRES-1/Rab4 human endogenous retrovirus locus have been associated with T-cell activation and disease manifestations in systemic lupus erythematosus (SLE).
    [Show full text]
  • Topoisomerase 1 Suppresses Replication Stress and Genomic Instability by Preventing Interference Between Replication and Transcription
    Topoisomerase 1 suppresses replication stress and genomic instability by preventing interference between replication and transcription. Sandie Tuduri, Laure Crabbé, Chiara Conti, Hélène Tourrière, Heidi Holtgreve-Grez, Anna Jauch, Véronique Pantesco, John de Vos, Aubin Thomas, Charles Theillet, et al. To cite this version: Sandie Tuduri, Laure Crabbé, Chiara Conti, Hélène Tourrière, Heidi Holtgreve-Grez, et al.. Topoi- somerase 1 suppresses replication stress and genomic instability by preventing interference between replication and transcription.. Nature Cell Biology, Nature Publishing Group, 2009, 11 (11), pp.1315- 1324. 10.1038/ncb1984. hal-00430775 HAL Id: hal-00430775 https://hal.archives-ouvertes.fr/hal-00430775 Submitted on 14 Jun 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Topoisomerase I suppresses genomic instability by preventing interference between replication and transcription Sandie Tuduri 1,2, Laure Crabbé 1, Chiara Conti 3, Hélène Tourrière 1, Heidi Holtgreve-Grez 4, Anna Jauch 4, Véronique Pantesco 5, John De Vos 5, Aubin
    [Show full text]
  • Table S1 the Four Gene Sets Derived from Gene Expression Profiles of Escs and Differentiated Cells
    Table S1 The four gene sets derived from gene expression profiles of ESCs and differentiated cells Uniform High Uniform Low ES Up ES Down EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol EntrezID GeneSymbol 269261 Rpl12 11354 Abpa 68239 Krt42 15132 Hbb-bh1 67891 Rpl4 11537 Cfd 26380 Esrrb 15126 Hba-x 55949 Eef1b2 11698 Ambn 73703 Dppa2 15111 Hand2 18148 Npm1 11730 Ang3 67374 Jam2 65255 Asb4 67427 Rps20 11731 Ang2 22702 Zfp42 17292 Mesp1 15481 Hspa8 11807 Apoa2 58865 Tdh 19737 Rgs5 100041686 LOC100041686 11814 Apoc3 26388 Ifi202b 225518 Prdm6 11983 Atpif1 11945 Atp4b 11614 Nr0b1 20378 Frzb 19241 Tmsb4x 12007 Azgp1 76815 Calcoco2 12767 Cxcr4 20116 Rps8 12044 Bcl2a1a 219132 D14Ertd668e 103889 Hoxb2 20103 Rps5 12047 Bcl2a1d 381411 Gm1967 17701 Msx1 14694 Gnb2l1 12049 Bcl2l10 20899 Stra8 23796 Aplnr 19941 Rpl26 12096 Bglap1 78625 1700061G19Rik 12627 Cfc1 12070 Ngfrap1 12097 Bglap2 21816 Tgm1 12622 Cer1 19989 Rpl7 12267 C3ar1 67405 Nts 21385 Tbx2 19896 Rpl10a 12279 C9 435337 EG435337 56720 Tdo2 20044 Rps14 12391 Cav3 545913 Zscan4d 16869 Lhx1 19175 Psmb6 12409 Cbr2 244448 Triml1 22253 Unc5c 22627 Ywhae 12477 Ctla4 69134 2200001I15Rik 14174 Fgf3 19951 Rpl32 12523 Cd84 66065 Hsd17b14 16542 Kdr 66152 1110020P15Rik 12524 Cd86 81879 Tcfcp2l1 15122 Hba-a1 66489 Rpl35 12640 Cga 17907 Mylpf 15414 Hoxb6 15519 Hsp90aa1 12642 Ch25h 26424 Nr5a2 210530 Leprel1 66483 Rpl36al 12655 Chi3l3 83560 Tex14 12338 Capn6 27370 Rps26 12796 Camp 17450 Morc1 20671 Sox17 66576 Uqcrh 12869 Cox8b 79455 Pdcl2 20613 Snai1 22154 Tubb5 12959 Cryba4 231821 Centa1 17897
    [Show full text]
  • The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia
    International Journal of Molecular Sciences Review The New Therapeutic Strategies in Pediatric T-Cell Acute Lymphoblastic Leukemia Marta Weronika Lato 1 , Anna Przysucha 1, Sylwia Grosman 1, Joanna Zawitkowska 2 and Monika Lejman 3,* 1 Student Scientific Society, Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] (M.W.L.); [email protected] (A.P.); [email protected] (S.G.) 2 Department of Pediatric Hematology, Oncology and Transplantology, Medical University of Lublin, 20-093 Lublin, Poland; [email protected] 3 Laboratory of Genetic Diagnostics, Medical University of Lublin, 20-093 Lublin, Poland * Correspondence: [email protected] Abstract: Childhood acute lymphoblastic leukemia is a genetically heterogeneous cancer that ac- counts for 10–15% of T-cell acute lymphoblastic leukemia (T-ALL) cases. The T-ALL event-free survival rate (EFS) is 85%. The evaluation of structural and numerical chromosomal changes is important for a comprehensive biological characterization of T-ALL, but there are currently no ge- netic prognostic markers. Despite chemotherapy regimens, steroids, and allogeneic transplantation, relapse is the main problem in children with T-ALL. Due to the development of high-throughput molecular methods, the ability to define subgroups of T-ALL has significantly improved in the last few years. The profiling of the gene expression of T-ALL has led to the identification of T-ALL subgroups, and it is important in determining prognostic factors and choosing an appropriate treatment. Novel therapies targeting molecular aberrations offer promise in achieving better first remission with the Citation: Lato, M.W.; Przysucha, A.; hope of preventing relapse.
    [Show full text]
  • A Novel Type of SYT/SSX Fusion
    A Novel Type of SYT/SSX Fusion: Methodological and Biological Implications Maria Törnkvist, M.Sc., Bertha Brodin, Ph.D., Armando Bartolazzi, M.D., Ph.D., Olle Larsson, M.D., Ph.D. Department of Cellular and Molecular Tumor Pathology, Cancer Centrum Karolinska, Karolinska Hospital (MT, BB, AB, OL), Stockholm, Sweden; and Department of Pathology, Regina Elena Cancer Institute (AB), Rome, Italy the presence of SYT/SSX transcripts in two cases Synovial sarcoma (SS) is a rare soft-tissue tumor using the proposed RT-PCR approach. Applications that affects children and young adults. It is charac- of optimized RT-PCR can contribute to reduce false- terized by the chromosomal translocation t(X; negative SYT/SSX SS cases reported in literature. 18)(p11.2;q11.2), which results in the fusion of the SYT gene on chromosome 18 with a SSX gene on KEY WORDS: RT-PCR, Synovial sarcoma, SYT/SSX chromosome X. In the majority of cases, SYT is fusion gene, SYT/SSX variants. fused to exon 5 of SSX1 (64%), SSX2 (36%), or, Mod Pathol 2002;15(6):679–685 rarely, SSX4. A novel fusion transcript variant deriv- ing from the fusion of SYT to exon 6 of SSX4 gene Synovial sarcomas (SS) account for 7 to 10% of all (SYT/SSX4v) was found coexpressed in one of the human soft-tissue sarcomas and are mainly located previously reported SYT/SSX4 cases. In the present in the extremities in the vicinity of large joints (1). investigation, we describe a new SS case that was Depending on histomorphological appearance, SSs previously shown to be negative for SYT/SSX1 and are usually subdivided into two major forms, bipha- SYT/SSX2 expression by conventional reverse tran- sic and monophasic.
    [Show full text]
  • Supplementary Tables
    Supp Table 1. Patient characteristics of samples used for colony assays, xenografts and intracellular colony assays Sr.No Age Sex Diagnosis Blast% Cytogenetics Mutations (IPSS) (AF%) Patient samples used for colony assays 1. 68 F Low risk 1% N/A None MDS 2. 78 M RAEB-1 7% N/A DNMT3A 3. 66 F High risk 12.2% 5q-,7q-,+11, DNMT3A MDS 20q- (28%) TP53 (58%) 4. 61 M High risk 6.2% Monosomy 7 ASXL1 (36%) MDS EZH2 (77%) RUNX1(18%) 5. 63 M Low risk Normal ETV6 (34%), MDS KRAS(15%), RUNX1 (40%), SRSF2 (43%), ZRSR2 (86%) 6. 62 F RAEB-2 Del 5q TP53 (7%) 7. 76 F t-MDS <1% Normal TET2(10%) 8. 80 M Low risk 5% Normal SF3B1(21%) MDS TET2(8%) ZRZR2(62%) 9. 74 F MPN 5% JAK2V617F+ 10. 76 M Low risk <1% Deletion Y None MDS 11. 84 M Low risk N/A N/A N/A MDS 12. 86 M Int-2 MDS 4-8% Normal U2AF1 (43%) blasts CBL (15%) 13. 64 M low risk 1-3% 20q deletion ASXL1 (17%) MDS SETBP1(17%) U2AF1(15%) 14. 81 F Low risk <1% Normal None MDS Patient samples used for PDX 15. 87 F Int-2 risk 1.2% Complex SETBP1 (38%) MDS cytogenetics, del 7, dup 11, del 13q 16. 59 F High-risk 7-10% Complex NRAS (12%), MDS cytogenetics RUNX1 (20%), (-5q31, -7q31, SRSF2 (22%), trisomy 8, del STAG2 (17%) 11q23 17. 79 F Int-2 risk 5-8% None MDS 18. 67 M MPN 6.6% Normal CALR (51%) IDH1(47%) PDGFRB (47%) Patient samples used for intracellular ASO uptake 19.
    [Show full text]
  • Supplemental Information
    Supplemental information Dissection of the genomic structure of the miR-183/96/182 gene. Previously, we showed that the miR-183/96/182 cluster is an intergenic miRNA cluster, located in a ~60-kb interval between the genes encoding nuclear respiratory factor-1 (Nrf1) and ubiquitin-conjugating enzyme E2H (Ube2h) on mouse chr6qA3.3 (1). To start to uncover the genomic structure of the miR- 183/96/182 gene, we first studied genomic features around miR-183/96/182 in the UCSC genome browser (http://genome.UCSC.edu/), and identified two CpG islands 3.4-6.5 kb 5’ of pre-miR-183, the most 5’ miRNA of the cluster (Fig. 1A; Fig. S1 and Seq. S1). A cDNA clone, AK044220, located at 3.2-4.6 kb 5’ to pre-miR-183, encompasses the second CpG island (Fig. 1A; Fig. S1). We hypothesized that this cDNA clone was derived from 5’ exon(s) of the primary transcript of the miR-183/96/182 gene, as CpG islands are often associated with promoters (2). Supporting this hypothesis, multiple expressed sequences detected by gene-trap clones, including clone D016D06 (3, 4), were co-localized with the cDNA clone AK044220 (Fig. 1A; Fig. S1). Clone D016D06, deposited by the German GeneTrap Consortium (GGTC) (http://tikus.gsf.de) (3, 4), was derived from insertion of a retroviral construct, rFlpROSAβgeo in 129S2 ES cells (Fig. 1A and C). The rFlpROSAβgeo construct carries a promoterless reporter gene, the β−geo cassette - an in-frame fusion of the β-galactosidase and neomycin resistance (Neor) gene (5), with a splicing acceptor (SA) immediately upstream, and a polyA signal downstream of the β−geo cassette (Fig.
    [Show full text]
  • A Novel FISH Assay for SS18–SSX Fusion Type in Synovial Sarcoma
    Laboratory Investigation (2004) 84, 1185–1192 & 2004 USCAP, Inc All rights reserved 0023-6837/04 $30.00 www.laboratoryinvestigation.org A novel FISH assay for SS18–SSX fusion type in synovial sarcoma Cecilia Surace1,2, Ioannis Panagopoulos1, Eva Pa˚lsson1, Mariano Rocchi2, Nils Mandahl1 and Fredrik Mertens1 1Department of Clinical Genetics, Lund University Hospital, Lund, Sweden and 2DAPEG, Section of Genetics, University of Bari, Bari, Italy Synovial sarcoma is a morphologically, clinically and genetically distinct entity that accounts for 5–10% of all soft tissue sarcomas. The t(X;18)(p11.2;q11.2) is the cytogenetic hallmark of synovial sarcoma and is present in more than 90% of the cases. It produces three types of fusion gene formed in part by SS18 from chromosome 18 and by SSX1, SSX2 or, rarely, SSX4 from the X chromosome. The SS18–SSX fusions do not seem to occur in other tumor types, and it has been shown that in synovial sarcoma a clear correlation exists between the type of fusion gene and histologic subtype and, more importantly, clinical outcome. Previous analyses regarding the type of fusion genes have been based on PCR amplification of the fusion transcript, requiring access to good- quality RNA. In order to obtain an alternative tool to diagnose and follow this malignancy, we developed a fluorescence in situ hybridization (FISH) assay that could distinguish between the two most common fusion genes, that is, SS18–SSX1 and SS18–SSX2. The specificity of the selected bacterial artificial chromosome clones used in the detection of these fusion genes, as well as the sensitivity of the analysis in metaphase and interphase cells, was examined in a series of 28 synovial sarcoma samples with known fusion gene status.
    [Show full text]
  • Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin
    Research Article Gene and Protein Expression Profiling of Human Ovarian Cancer Cells Treated with the Heat Shock Protein 90 Inhibitor 17-Allylamino-17-Demethoxygeldanamycin Alison Maloney,1 Paul A. Clarke,1 Soren Naaby-Hansen,3,4 Rob Stein,3,5 Jens-Oliver Koopman,3,4 Akunna Akpan,3,4 Alice Yang,3,4 Marketa Zvelebil,3,4 Rainer Cramer,3,4 Lindsay Stimson,1 Wynne Aherne,1 Udai Banerji,1,2 Ian Judson,1,2 Swee Sharp,1 Marissa Powers,1 Emmanuel deBilly,1 Joanne Salmons,1 Michael Walton,1 Al Burlingame,3,4 Michael Waterfield,3,4 and Paul Workman1 1Haddow Laboratories, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research; 2Royal Marsden NHS Foundation Trust, Sutton, Surrey, United Kingdom; 3Ludwig Institute for Cancer Research and Departments of 4Biochemistry and Molecular Biology and 5Oncology, University College London, London, United Kingdom Abstract anticancer agents and provide a means of obtaining a detailed The promising antitumor activity of 17-allylamino-17-deme- molecular signature of drug action (1, 2). In addition, these thoxygeldanamycin (17AAG) results from inhibition of the methods may identify pharmacodynamic markers that can be used molecular chaperone heat shock protein 90(HSP90)and to evaluate drugs in clinical trials. Gene expression microarrays are subsequent degradation of multiple oncogenic client proteins. increasingly used to investigate the molecular responses to cancer Gene expression microarray and proteomic analysis were used drugs in tumor cells (1). Although valuable, analysis of gene to profile molecular changes in the A2780human ovarian expression at the mRNA level alone cannot adequately predict cancer cell line treated with 17AAG.
    [Show full text]
  • Analysis of Genomic Aberrations and Gene Expression Profiling Identifies
    Citation: Blood Cancer Journal (2011) 1, e40; doi:10.1038/bcj.2011.39 & 2011 Macmillan Publishers Limited All rights reserved 2044-5385/11 www.nature.com/bcj ORIGINAL ARTICLE Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms KL Rice1, X Lin1, K Wolniak1, BL Ebert2, W Berkofsky-Fessler3, M Buzzai4, Y Sun5,CXi5, P Elkin5, R Levine6, T Golub7, DG Gilliland8, JD Crispino1, JD Licht1 and W Zhang5 1Division of Hematology/Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; 2Division of Hematology, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA; 3Translational Research Sciences, Hoffmann-La Roche, Inc., Nutley, NJ, USA; 4Oncology, Novartis, Origgio, VA, Italy; 5Division of Hematology/ Oncology, Department of Medicine, Center of Biomedical Informatics, Mount Sinai School of Medicine, New York, NY, USA; 6Human Oncology and Pathogenesis Program and Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA; 7The Eli and Edythe L. Broad Institute of Massachusetts Institute of Technology and Harvard University, Cambridge, MA, USA and 8Oncology, Merck Research Laboratories, North Wales, PA, USA Polycythemia vera (PV), essential thrombocythemia and by a recurrent mutation, JAK2V617F, which is present in B95% primary myelofibrosis, are myeloproliferative neoplasms of patients with PV, B65% with PMF and B55% with ET.2 JAK2 (MPNs) with distinct clinical features and are associated with is one member of the Janus family of non-receptor tyrosine the JAK2V617F mutation. To identify genomic anomalies involved in the pathogenesis of these disorders, we profiled kinases that transduces signals downstream of type I and II 87 MPN patients using Affymetrix 250K single-nucleotide cytokine receptors via signal transducer and activators of polymorphism (SNP) arrays.
    [Show full text]
  • Aneuploidy: Using Genetic Instability to Preserve a Haploid Genome?
    Health Science Campus FINAL APPROVAL OF DISSERTATION Doctor of Philosophy in Biomedical Science (Cancer Biology) Aneuploidy: Using genetic instability to preserve a haploid genome? Submitted by: Ramona Ramdath In partial fulfillment of the requirements for the degree of Doctor of Philosophy in Biomedical Science Examination Committee Signature/Date Major Advisor: David Allison, M.D., Ph.D. Academic James Trempe, Ph.D. Advisory Committee: David Giovanucci, Ph.D. Randall Ruch, Ph.D. Ronald Mellgren, Ph.D. Senior Associate Dean College of Graduate Studies Michael S. Bisesi, Ph.D. Date of Defense: April 10, 2009 Aneuploidy: Using genetic instability to preserve a haploid genome? Ramona Ramdath University of Toledo, Health Science Campus 2009 Dedication I dedicate this dissertation to my grandfather who died of lung cancer two years ago, but who always instilled in us the value and importance of education. And to my mom and sister, both of whom have been pillars of support and stimulating conversations. To my sister, Rehanna, especially- I hope this inspires you to achieve all that you want to in life, academically and otherwise. ii Acknowledgements As we go through these academic journeys, there are so many along the way that make an impact not only on our work, but on our lives as well, and I would like to say a heartfelt thank you to all of those people: My Committee members- Dr. James Trempe, Dr. David Giovanucchi, Dr. Ronald Mellgren and Dr. Randall Ruch for their guidance, suggestions, support and confidence in me. My major advisor- Dr. David Allison, for his constructive criticism and positive reinforcement.
    [Show full text]